期刊
LANCET
卷 382, 期 9903, 页码 1525-1533出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(13)61809-7
关键词
-
资金
- National Institute of Allergy and Infectious Diseases (NIAID) [K24 AI069994]
- DARE: Delaney AIDS Research Enterprise [U19AI096109]
- University of California, San Francisco (UCSF)/Gladstone Center for AIDS Research (CFAR) [P30 AI027763]
- NIAID [1R56AI095073-01A1, A151982]
- Burnet Institute
- UCSF/Gladstone CFAR [A1027763]
The success of antiretroviral therapy has led some people to now ask whether the end of AIDS is possible. For patients who are motivated to take therapy and who have access to lifelong treatment, AIDS-related illnesses are no longer the primary threat, but a new set of HIV-associated complications have emerged, resulting in a novel chronic disease that for many will span several decades of life. Treatment does not fully restore immune health; as a result, several inflammation-associated or immunodeficiency complications such as cardiovascular disease and cancer are increasing in importance. Cumulative toxic effects from exposure to antiretroviral drugs for decades can cause clinically-relevant metabolic disturbances and end-organ damage. Concerns are growing that the multimorbidity associated with HIV disease could affect healthy ageing and overwhelm some health-care systems, particularly those in resource-limited regions that have yet to develop a chronic care model fully. In view of the problems inherent in the treatment and care for patients with a chronic disease that might persist for several decades, a global effort to identify a cure is now underway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据